Govt boosts family planning with new transport facility
This information was conveyed to civil surgeons across various districts by Priya Ranjan Raju, officer on special duty (OSD) and in charge of referral transport.
It is worth noting that this facility was already available to other categories such as women after childbirth, newborns and patients with critical illnesses. Going forward, the service will also cover individuals undergoing sterilisation and vasectomy procedures.
Civil surgeons and district programme officers have been instructed to ensure that these beneficiaries are transported home via the 102 ambulance service following their operations.
According to health department sources, the aim of the initiative is to strengthen and promote the family planning programme. Saran civil surgeon Dr Sagar Dulal Sinha said that family planning services are available across all health centres, from primary health centres to other government hospitals.
He added that other methods of family planning such as Mala-N, Copper T and others are also provided at govt facilities.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 days ago
- Economic Times
Monitor presence of potentially carcinogenic chemical in Ranitidine: DCGI to drug controllers
New Delhi: Drug regulator DCGI has asked drug controllers of all states and Union Territories to direct manufacturers under their jurisdiction to monitor the presence of a potentially carcinogenic chemical -- N-Nitrosodimethylamine -- in antacid Ranitidine. Ranitidine is used to reduce the amount of acid the stomach makes and also in the treatment of acid reflux and stomach or intestinal ulcers among issue related to safety of Ranitidine drug due to presence of N-Nitrosodimethylamine (NDMA) impurity has been under consideration for quite some time now and various measures have been taken from time to time, the Drugs Controller General of India (DCGI) said in a communication on July 24. An expert-committee was constituted in December last year and the report of the expert committee was placed before the 92nd Drugs Technical Advisory Board (DTAB) meeting in April this year, the communication, which also had minutes of the DTAB meeting as enclosures, said. The communication said DTAB, after detailed deliberation, recommended that a larger committee is required to be constituted which will look into all the aspects, including the storage conditions of Ranitidine. Also it suggested that the Indian Council of Medical Research (ICMR) may conduct a study for assessing the safety of Ranitidine drug considering the presence of NDMA impurity. "The manufacturers should monitor the NDMA levels in the API/formulation and also take risk based measures such as reducing the shelf life etc," the communication said. "In view of above, as recommended by DTAB, you are requested to direct the manufacturers under your jurisdiction to monitor the NDMA levels in the API/formulation of Ranitidine and also take risk-based measures such as reducing the shelf life etc," it added.
Time of India
4 days ago
- Time of India
Monitor presence of potentially carcinogenic chemical in Ranitidine: DCGI to drug controllers
New Delhi: Drug regulator DCGI has asked drug controllers of all states and Union Territories to direct manufacturers under their jurisdiction to monitor the presence of a potentially carcinogenic chemical -- N-Nitrosodimethylamine -- in antacid Ranitidine. Ranitidine is used to reduce the amount of acid the stomach makes and also in the treatment of acid reflux and stomach or intestinal ulcers among others. Explore courses from Top Institutes in Please select course: Select a Course Category Healthcare others Leadership Data Science Operations Management MBA Others Digital Marketing Management Data Science Product Management Public Policy Artificial Intelligence healthcare CXO Project Management Finance Design Thinking Data Analytics Degree Cybersecurity Skills you'll gain: Financial Analysis in Healthcare Financial Management & Investing Strategic Management in Healthcare Process Design & Analysis Duration: 12 Weeks Indian School of Business Certificate Program in Healthcare Management Starts on Jun 13, 2024 Get Details The issue related to safety of Ranitidine drug due to presence of N-Nitrosodimethylamine (NDMA) impurity has been under consideration for quite some time now and various measures have been taken from time to time, the Drugs Controller General of India (DCGI) said in a communication on July 24. An expert-committee was constituted in December last year and the report of the expert committee was placed before the 92nd Drugs Technical Advisory Board (DTAB) meeting in April this year, the communication, which also had minutes of the DTAB meeting as enclosures, said. The communication said DTAB, after detailed deliberation, recommended that a larger committee is required to be constituted which will look into all the aspects, including the storage conditions of Ranitidine. Live Events Also it suggested that the Indian Council of Medical Research (ICMR) may conduct a study for assessing the safety of Ranitidine drug considering the presence of NDMA impurity. "The manufacturers should monitor the NDMA levels in the API/formulation and also take risk based measures such as reducing the shelf life etc," the communication said. "In view of above, as recommended by DTAB, you are requested to direct the manufacturers under your jurisdiction to monitor the NDMA levels in the API/formulation of Ranitidine and also take risk-based measures such as reducing the shelf life etc," it added.
Time of India
4 days ago
- Time of India
Monitor NDMA levels in antacid Ranitidine: Drugs body CDSCO
NEW DELHI: Drug controllers of all states and UTs have been asked by Central Drugs Standard Control Organisation (CDSCO) to direct manufacturers under their jurisdiction to monitor levels of NDMA in the active pharmaceutical ingredient or drug formulation of Ranitidine, a commonly used antacid. NDMA (N-nitrosodimethylamine) is a chemical which has been recognised as a probable carcinogen by International Agency for Research on Cancer (IARC), reports Durgesh Nandan Jha. CDSCO's decision came after reports of NDMA impurity in the medicine. An expert panel was appointed to deliberate on the concern in Dec last year. Sources said the the committee's recommendations were deliberated in a meeting of Drug Technical Advisory Body recently. DTAB recommended that a larger committee be constituted to look into all aspects, including storage conditions of Ranitidine, and also suggested that the Indian Council of Medical Research undertake a study to assess the drug's safety in addition to directing manufacturers to monitor NDMA levels in the drug and, if required, take risk-based measures such as reducing the shelf life.
